New drug blocks pancreatic cancer growth in mice, study finds

A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai. The study, published recently in the journal Gastroenterology, also demonstrated in mice that the drug, called Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies.

"This is an exciting step toward improving survival rates in pancreatic cancer patients," said study lead author Mouad Edderkaoui, PhD, assistant professor of Medicine and Biomedical Sciences at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. "If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma (PDAC), which is very difficult to treat."

Pancreatic cancer is the third-leading cause of cancer-related death in the United States, according to the American Cancer Society. This year, about 55,000 people in the U.S. will be diagnosed with the disease and more than 44,000 will die, making it one of the deadliest cancers. The pancreatic cancer five-year survival rate is 7 percent.

Ninety-five percent of pancreatic cancer patients are diagnosed with PDAC, which develops from cells lining small tubes in the pancreas. PDAC can be difficult to treat because the cancer cells prompt normal cells that reside in the pancreas--called stellate cells--to produce pancreatic scar tissue. Scar tissue makes it difficult for chemotherapy agents and blood to enter the pancreas, said study senior author Stephen J. Pandol M.D., director of Basic and Translational Pancreas Research at Cedars-Sinai.

The cancer and stellate cell interaction also creates an environment that stimulates local tumor growth and cancer spread to distant sites in the body, said Pandol, a professor of Medicine at Cedars-Sinai. Additionally, the activity levels of certain enzymes rev up, fueling resistance to cancer treatments.

"I've seen patients who respond to therapy for a while, and then the disease takes off because the cancer becomes smart--it blocks chemotherapy from working," Pandol said. "Metavert targets that action."

Over a four-year period, the investigators designed and synthesized new chemicals that inhibit cancer cell activity. They discovered that Metavert blocked drug resistance and also significantly boosted the positive effects of radiation and two chemotherapy agents commonly used in humans. In one of the mouse studies, Metavert increased the survival rate by about 50 percent.

The investigators currently are developing a version of the drug to test in humans, Pandol said.

Edderkaoui M, Chheda C, Soufi B, Zayou F, Hu R, Ramanujan VK, Pan X, Boros LG, Tajbakhsh J, Madhav A, Bhowmick N, Wang Q, Lewis M, Tuli R, Habtezion A, Murali R, Pandol SJ.
An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
Gastroenterology. 2018 Aug 22. doi: 10.1053/j.gastro.2018.08.028.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...